The law firm of Kirby McInerney LLP is investigating potential claims against Keros Therapeutics, Inc. (“Keros” or the “Company”) (NASDAQ: KROS). The investigation concerns whether Keros and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.

[Click here to learn more about the investigation]

On December 12, 2024, Keros issued a press release “announcing that it had voluntarily halted dosing in the 3.0 mg/kg and 4.5mg/kg treatment arms in the ongoing TROPOS trial, a Phase 2 clinical trial of cibotercept (KER-012) in combination with background therapy in patients with pulmonary arterial hypertension (“PAH”), based on a safety review due to the unanticipated observation of pericardial effusion adverse events in the trial.” On this news, the price of Keros shares declined by $50.22 per share, or approximately 73.15%, from $68.65 per share on December 11, 2024, to close at $18.43 on December 12, 2024.

Then, on January 15, 2025, Keros issued a press release “announcing that it has voluntarily halted all dosing in the TROPOS trial, a Phase 2 clinical trial of cibotercept (KER-012) in combination with background therapy in patients with PAH, including the 1.5 mg/kg and placebo treatment arms, based on the ongoing safety review due to new observations of pericardial effusion adverse events.” Keros further stated that “the Company has notified investigators and certain regulatory authorities, including the FDA, about this decision, and is in the process of notifying other relevant regulatory authorities.” On this news, the price of Keros shares declined by $2.06 per share, from $12.48 per share on January 14, 2025, to close at $10.42 on January 15, 2025.

If you purchased or otherwise acquired Keros securities, have information, or would like to learn more about this investigation, contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or by filling out this CONTACT FORM, to discuss your rights or interests with respect to these matters without any cost to you.

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250122883696/en/